307 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
15 Feb 24
Results of Operations and Financial Condition
8:10am
, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
for the development and commercialization of certain
products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk
8-K
EX-99.1
9v73bv2s
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
o0344c 0smhxin2rmz6
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
EX-99.1
g5j 1rv1887c4z0tnwi
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
36mf9
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
wted92
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
EX-99.1
p5zr o9oftcddyok
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
141l ri60
27 Oct 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.2
nefl7d10ykf2v3p1ov
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm
8-K
EX-99.1
2werd
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm